Item 1.01 Entry into a Material Definitive Agreement.

On September 10, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the "Company"), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company, Erik Emerson, Lokahi Therapeutics, Inc., a Nevada corporation, FreeT Inc., a company organized under the laws of the Republic of Korea (f/k/a Inscobee Inc.) ("FreeT"), and Apimeds Inc., a South Korean corporation and wholly owned subsidiary of FreeT (together with FreeT, the "Inscobee Parties"), entered into the First Amendment to Confidential Settlement and Mutual Release Agreement (the "Amendment"), which amends the Confidential Settlement and Mutual Release Agreement, dated April 24, 2026 (the "Settlement Agreement"), among the Company, MindWave Innovations Inc, Lokahi Therapeutics, Inc., Erik Emerson, Inscobee Inc. (n/k/a FreeT Inc.), and Apimeds Inc.

The Amendment amends Section 10(a) of the Settlement Agreement to restructure the composition of the Company's board of directors (the "Board"). During the interim period between the effective date of the Settlement Agreement and the Preferred Stock Conversion (as defined in the Settlement Agreement), the Board shall consist solely of Elona Kogan, Carol O'Donnell, Dr. Bennett Weintraub, and Sungjoon Chae, none of whom may be removed without the written consent of Dr. Vin Menon ("Menon") and the Inscobee Parties. Following such interim period, the Board shall consist of seven members: four independent directors nominated by MindWave, two directors nominated by Menon (one of whom shall be Menon), and Sungjoon Chae.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 10, 2026, pursuant to the Settlement Agreement, as amended by the Amendment (each as defined in Item 1.01 above), the Board appointed Sungjoon Chae to serve as a member of the Board, effective as of such date.

Sungjoon Chae was appointed to the Board pursuant to a nomination by the Inscobee Parties under the Settlement Agreement, as amended by the Amendment. Other than the foregoing, there are no arrangements or understandings between Sungjoon Chae and any other persons pursuant to which he was selected as a director of the Company.

There are no family relationships between Sungjoon Chae and any of the Company's officers and directors.

There are no related party transactions between the Company and Sungjoon Chae that would require disclosure under Item 404(a) of Regulation S-K.

The material terms of Sungjoon Chae's compensation arrangements as a director have not yet been determined as of the date of this Current Report on Form 8-K and will be disclosed once finalized. Mr. Chae has served as Co-Chief Executive Officer of the Company since May 4, 2026.